Adlai Nortye Group Ltd. (ANL)
NASDAQ: ANL · Real-Time Price · USD
15.22
-0.30 (-1.93%)
At close: Sep 17, 2026, 4:00 PM EDT
15.28
+0.06 (0.39%)
After-hours: Sep 17, 2026, 4:50 PM EDT
Adlai Nortye Group Revenue
Adlai Nortye Group had revenue of $13.06M in the half year ending June 30, 2026. This brings the company's revenue in the last twelve months to $18.06M. In the year 2025, Adlai Nortye Group had annual revenue of $5.00M.
Revenue (ttm)
$18.06M
Revenue Growth
n/a
P/S Ratio
53.96
Revenue / Employee
$165,651
Employees
109
Market Cap
980.14M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.00M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 45.73M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
ANL News
- 1 day ago - Adlai Nortye Group Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 7 days ago - Adlai Nortye initiated with a Buy at Jefferies - TheFly
- 9 days ago - Adlai Nortye doses first patient in AN4035 trial - TheFly
- 9 days ago - Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC - GlobeNewsWire
- 9 days ago - Adlai Nortye assumed with a Buy at Lucid Capital - TheFly
- 4 weeks ago - Adlai Nortye Group Earnings release: Q2 2026 - Filings
- 4 weeks ago - Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress - GlobeNewsWire
- 6 weeks ago - Adlai Nortye submits clinical trial notification to Australia TGA for AN4035 - TheFly